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Cost Effectiveness of Enoxaparin in
Acute ST-Segment Elevation Myocardial Infarction
The ExTRACT–TIMI 25 (Enoxaparin and Thrombolysis Reperfusion
for Acute Myocardial Infarction Treatment–Thrombolysis In
Myocardial Infarction 25) Study
Leo Marcoff, MD,* Zugui Zhang, PHD,* Wei Zhang, MS,* Edward Ewen, MD,*
Claudine Jurkovitz, MD, MPH,* Prisca Leguet, PHARMD,† Paul Kolm, PHD,*
William S. Weintraub, MD*
Newark, Delaware; and Paris, France
Objectives We used a U.S. model of health care costs to examine the cost effectiveness of enoxaparin compared with un-
fractionated heparin (UFH) as adjunctive therapy for fibrinolysis in patients with ST-segment elevation myocar-
dial infarction (STEMI).
Background The ExTRACT–TIMI 25 (Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment–
Thrombolysis In Myocardial Infarction 25) study, a large, randomized, multinational trial, demonstrated a reduc-
tion in death or nonfatal myocardial infarction when enoxaparin was used instead of UFH as adjunctive therapy
for fibrinolysis in patients with STEMI.
Methods We used patient-level clinical outcomes and resource use from the ExTRACT–TIMI 25 trial and estimates of life ex-
pectancy gains as a result of the prevention of the clinical events on the basis of the Framingham Heart Study.
Results Index hospitalization costs trended lower by $126 in the enoxaparin group (95% confidence interval [CI]: $295
to $49). Thirty-day costs trended higher by $102 for enoxaparin (95% CI: $108 to $314). Patients receiving
enoxaparin gained an average of 0.12 life-years relative to patients given UFH. Estimated total lifetime costs
were $1,207 higher in the enoxaparin group (95% CI: $491 to $1,923). The incremental cost-effectiveness ratio
of enoxaparin compared with UFH was $5,700 per life-year gained, with 99.9% of bootstrap-derived estimates
$50,000 per life-year gained. Using a probabilistic sensitivity analysis, there is a 90% probability that enoxapa-
rin is cost effective for lifetime, provided that the willingness-to-pay value exceeds $50,000.
Conclusions Based on a U.S. model of health care economics, the strategy of using enoxaparin instead of UFH as adjunctive
therapy for fibrinolysis in patients with STEMI is cost effective according to commonly used benchmarks. (J Am
Coll Cardiol 2009;54:1271–9) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.05.060d
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rhe ExTRACT–TIMI 25 (Enoxaparin and Thrombolysis
eperfusion for Acute Myocardial Infarction Treatment–
hrombolysis In Myocardial Infarction 25) study compared
noxaparin, a low-molecular-weight heparin (LMWH),
nd unfractionated heparin (UFH) as adjunctive therapy for
brinolysis in patients with ST-segment elevation myocar-
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Manuscript received March 17, 2009; accepted May 13, 2009.ial infarction (STEMI) (1). The trial demonstrated the
linical benefit of enoxaparin over UFH, with a 17% relative
isk reduction and 2.1% absolute risk reduction of death or
onfatal recurrent myocardial infarction (MI). In addition,
here was a reduction in the composite of death, nonfatal
einfarction, or urgent revascularization. While the inci-
ence of major bleeding episodes was increased in patients
andomly assigned to enoxaparin, the net clinical benefit of
noxaparin over UFH was shown by the decreased occur-
ence of the composites of death, nonfatal MI, and impor-
ant safety outcomes, namely, nonfatal disabling stroke,
onfatal major bleeding, and nonfatal intracranial hemor-
hage. The present study evaluates short- and long-term
ost effectiveness of using enoxaparin compared with UFH
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lysis in patients with STEMI.
Methods
Design of the ExTRACT–
TIMI 25 trial. The ExTRACT–
TIMI 25 study (Clinical Trials no.
NCT00077792), a large, random-
ized, double-blind, multinational
trial, has been described previously
(1,2). Briefly, between October 24,
2002, and October 1, 2005, 20,506
patients with STEMI were ran-
domized at 674 sites in 48 coun-
tries (Online Table A) to receive
either enoxaparin or UFH as ad-
junctive therapy to fibrinolytic
agents. Study medication was ad-
ministered in a double-blind
fashion with the use of a double-
dummy design between 15 min
before and 30 min after the ini-
tiation of fibrinolysis, and oc-
curred within 30 min after ran-
domization. Patients were eligible
if they were at least 18 years of age,
had at least 20 min of ischemic
symptoms while at rest within 6 h
efore randomization, had ST-segment elevation of at least 0.1
V in 2 limb leads or of 0.2 mV in at least 2 contiguous
recordial leads or had left bundle branch block, and were
cheduled to undergo fibrinolysis therapy with streptokinase,
enecteplase, alteplase, or reteplase. Exclusion criteria were
ardiogenic shock, pericarditis, symptoms of aortic dissection,
ontraindications to fibrinolysis, receipt of a LMWH within
he prior 8 h, known renal insufficiency (defined by a serum
reatinine level of220mol/l [2.5 mg/dl] for men and175
mol/l [2.0 mg/dl] for women), or a life expectancy of 12
onths. The primary efficacy end point was the composite of
eath from any cause or nonfatal recurrent MI. In addition, 3
et clinical benefit end points were pre-specified in the form of
omposites of death, nonfatal MI, and important safety out-
omes, including nonfatal disabling stroke, nonfatal major
leeding, and nonfatal intracranial hemorrhage. Approval for
he study was obtained through the local institutional review
oard at each participating center.
conomic analysis plan and cost assessment. We com-
ared the costs of the 2 interventions and performed an
ncremental cost-effectiveness analysis (3,4). Costs and cost
ffectiveness were assessed at 30 days and lifetime. Direct
edical care costs associated with index hospitalizations, sub-
equent hospitalizations, and subsequent outpatient procedures
ere considered in this analysis. Data were not available to
alculate the costs of concomitant medication and indirect
Abbreviations
and Acronyms
CI  confidence interval
DRG  diagnosis-related
group
ICC  intracluster
correlation coefficient
ICER  incremental cost-
effectiveness ratio
IQR  interquartile range
LMWH  low-molecular-
weight heparin
LYG  life-years gained
LYL  life-years lost
MI  myocardial infarction
NHB  net health benefit
NMB  net monetary
benefit
PCI  percutaneous
coronary intervention
QALY  quality-adjusted
life-year
STEMI  ST-segment
elevation myocardial
infarction
UFH  unfractionated
heparinosts due to lost productivity, but the overall perspective was aocietal. Thirty-day costs were not discounted because the
uration of the trial was1 year. Costs beyond the trial period
ere discounted 3% annually after the first year. All costs used
004 as the base year. The data collected at 30 days included
he details of the index hospitalization, including length of stay,
ehospitalizations, major procedures, interventions (for exam-
le, cardiac catheterization, percutaneous coronary intervention
PCI], coronary artery bypass graft surgery, intra-aortic balloon
ump, computed tomography scan, and magnetic resonance
maging), and resource use associated with severe adverse events.
The index and subsequent hospitalizations for patients
nrolled in the ExTRACT–TIMI 25 trial were assigned a
iagnosis-related group (DRG) in accordance with U.S.
edicare diagnostic standards. Costs for each DRG were
stimated using average Medicare reimbursement rates ob-
ained from the Medicare Part A data file (5), and physician
osts were estimated as a percent share by DRG according to
he methods of Mitchell et al. (6). Outpatient procedures were
oded by Current Procedural Terminology, and assigned a cost
ased on the Medicare fee schedule (Online Table B). Costs
eyond the trial period were estimated as the average per capita
articipant national health expenditures of $5,219 in 2004 (7).
Given the high cost differences between enoxaparin and
FH, it is necessary to incorporate the cost of both
noxaparin and UFH in the economic analysis. Therefore,
he costs of enoxaparin and UFH were included in the
nalysis based on the observed utilization in the Ex-
RACT–TIMI 25 study. As per protocol, treatment with
noxaparin lasted a median of 7.0 days (interquartile range
IQR] 4.5 to 7.5 days), and treatment with UFH lasted a
edian of 2.0 days (IQR 2.0 to 2.2 days). In the enoxaparin
roup, the initial bolus was 30 mg and the subsequent daily
ose was 140 mg until hospital discharge. It was assumed
hat the treatment was given for an average of 7 days. In the
FH group, the initial bolus was assumed to be 4,000 IU,
nd the next infusion was 1,000 IU/h for 48 h. The unit
rices for UFH and enoxaparin were derived from the prices
n 2004. The cost of treatment with enoxaparin was esti-
ated to be $214, and the cost of treatment with UFH was
stimated to be $13.
ife expectancy estimation. Age- and sex-specific life ex-
ectancy was estimated from Framingham Heart Study data
8). In the event of death, life-years lost (LYL) were obtained
y subtracting the in-trial survival times from estimated age-
nd sex-specific life expectancy estimates for patients with
ardiovascular disease (9,10). For patients who experienced
ultiple events of different types during the trial, LYL was
stimated assuming a hierarchy of death, stroke, and MI.
verage LYL was calculated for both treatment groups, and
heir difference (UFH  enoxaparin) yielded an estimate of
ife-years gained (LYG) with enoxaparin. LYL were dis-
ounted 3% annually after the first year.
stimation of cost effectiveness. The cost-effectivenessnalysis was performed for periods of 30 days and lifetime.
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September 29, 2009:1271–9 Cost Effectiveness of Enoxaparin in STEMIhe cost effectiveness was expressed as the incremental
ost-effectiveness ratio (ICER), which is the cost divided by
YG. Bootstrap methods were used to estimate 95%
onfidence interval (CI) for both cost and LYG (11). To
ddress the uncertainty of the effect of death, MI, or stroke
n LYG, traditional 1-way sensitivity analyses were per-
ormed by varying LYG by 10%, 20%, 30%, and 40% (12).
robabilistic sensitivity analysis was conducted to assess the
mpact of all sources of uncertainty involved in the calcula-
ion of cost and LYG (13–15). The probability assumptions
f effectiveness were derived from American Heart Associ-
tion statistics (16) and the Cardiovascular Health Study
17). Monte Carlo simulation was performed to derive the
ifferences in quality-adjusted life-years (QALY) and mean
ost between the enoxaparin group and the UFH group.
ubgroup analysis and net benefit analysis. Cost and
ffectiveness analysis were conducted for subgroups, defined
ccording to age, sex, body mass index, prior MI, prior heart
ailure, diabetes mellitus, prior unstable angina, prior PCI or
oronary artery bypass graft surgery, and platelet count. Net
enefit analysis (net monetary benefit [NMB] and net
ealth benefit [NHB]) were applied to the 30-day cost-
ffectiveness analysis (18,19).
Based on the method proposed by Manca et al. (20),
MB and NHB were calculated at the patient level (21)
rom patient level data on cost and effectiveness:
NMBiEiCi
NHBiEiCi ⁄
linical SummaryTable 1 Clinical Summary
Baseline Characteristics Enoxap
Age, yrs
Male
Weight, kg
Hypertension 4,5
Current smoker 4,8
Diabetes mellitus 1,5
Prior MI 1,3
Unfractionated heparin within 3 h before randomization 1,6
LMWH within 7 days before randomization
Creatinine clearance, ml/min
Time (h) from symptom onset to start of fibrinolytic therapy
Outcomes at 30 days
Primary efficacy end point (death or nonfatal MI)
Death
Nonfatal MI
Urgent revascularization
Death, nonfatal MI, or urgent revascularization
Net clinical benefit at 30 days
Death, nonfatal MI, or nonfatal disabling stroke
Death, nonfatal MI, or nonfatal major bleeding
Death, nonfatal MI, or nonfatal intracranial hemorrhagealues are mean  SD, n (%), or mean  SD (n).
LMWH  low molecular weight heparin; MI  myocardial infarction.here Ci and Ei are the cost and effectiveness (QALY) at
he i-th patient, and  is the willingness-to-pay value.
tandard regression methods were applied to the analysis of
reatment group differences with respect to NMB or NHB.
Because of the multisite, multicountry design of the trial,
ost and effectiveness data were essentially clustered; that is,
ata specific to a given site or country may be correlated
21,22). Therefore, multilevel (hierarchical) regression
odels of net benefit were used to account for the intra-
luster correlation (ICC) (21,22). A 2-level hierarchical
odel method was applied: country-level and patient-level
23). An empirical Bayesian shrinkage factor was applied to
stimate country-specific cost effectiveness.
To investigate the primary reason for discrepancy be-
ween NMB and NHB, the ICC was calculated based on
he multilevel regression models. The ICC is defined from
he variance components estimated from the multilevel
egression models and takes values between 0 and 1 inclu-
ively. It can be interpreted as the percentage of the total
ariance attributed to between-country variation. While a
eneral ICC for country variation was reported based on the
ariance component specification, an ICC for each arm of the
rial was defined based on the random coefficient specification.
high ICC indicates that the dataset is clustered, which
eans that variation between countries is an important com-
onent of the total variation and that countries differ substan-
ially in measured health outcomes, namely, NMB and NHB,
ncluding cost and effectiveness.
n  10,256) Heparin (n  10,223) p Value
12 60 12 0.35
,841 (76) 7,855 (77) 0.52
15 (9,689) 77 14 (9,697) 0.22
,128 (45) 4,401/10,105 (44) 0.18
,254 (47) 4,837/10,215 (47) 0.99
,145 (15) 1,515/10,104 (15) 0.64
,214 (13) 1,310/10,190 (13) 0.46
,255 (16) 1,608/10,223 (16) 0.69
43 (0.4) 50 (0.5) 0.46
35 (9,250) 127 35 (9,318) 0.23
1.6 (10,206) 3.3 1.4 (10,189) 0.66
,017 (10) 1,223 (12) 0.001
708 (6.9) 765 (7.5) 0.11
309 (3.0) 458 (4.5) 0.001
213 (2.1) 286 (2.8) 0.001
,199 (12) 1,479 (15) 0.001
,038 (10) 1,260 (12) 0.001
,128 (11) 1,305 (13) 0.001
,040 (10) 1,250 (12) 0.001arin (
60
7
78
05/10
55/10
45/10
49/10
34/10
135
3.3
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Cost Effectiveness of Enoxaparin in STEMI September 29, 2009:1271–9esults
ummary of clinical data. Of a total of 20,506 patients
ho were randomized, 20,479 were included in the
ntention-to-treat analysis. The patients were well matched
or baseline characteristics and were similar to populations
tudied in contemporary trials of interventions for STEMI
1) (Table 1). In addition, the treatment groups were well
atched with respect to concomitant therapy with other
uideline-recommended treatments, such as aspirin, beta-
lockers, and inhibitors of the renin-angiotensin system.
he majority of patients received all of the above
reatments.
Treatment with enoxaparin lasted a median of 7.0 days
defined as 24-h intervals after randomization [IQR 4.5 to
.5 days]), and treatment with UFH lasted a median of 2.0
ays (IQR 2.0 to 2.2 days) (1). The median duration of
ospitalization for the study population was 10 days (IQR 7
o 17 days). Most patients were treated with medical
herapy only; PCI was used in 23.0% of patients (as rescue
herapy in 2.8% and as urgent or elective procedure in
0.2%), and coronary artery bypass graft surgery was per-
ormed in 2.8% of patients.
The primary end point was ascertained at 30 days in all
ut 3 patients in the intention-to-treat population. The rate
f death or nonfatal MI was 9.9% in the enoxaparin group
ealth State-Specific Life Expectancyy Age and Sex From Framingham DataTable 2 Health Stat -Specific Life Expectancyby Age and Sex From Framingham Data
Sex, Age (Yrs) Cardiovascular Disease Acute MI Stroke
Males
50 15.9 13.9 NA
60 12.3 10.8 7.98
70 8.78 7.48 5.50
80 5.26 4.30 3.75
Females
50 20.3 14.9 NA
60 16.1 11.6 9.81
70 11.0 7.18 7.11
80 7.02 5.34 4.96
/A  not available; other abbreviation as in Table 1.
osts, Life-Years Lost, and QALY of 30 Days and Lifetime by TreatmTable 3 Costs, Life-Years Lost, and QALY of 30 Days and Lifeti
Item Enoxaparin (n  10,256)
Total 30-day costs* $11,129.00
Index hospitalization $9,620.20
Subsequent hospitalizations $1,209.50
Subsequent outpatient procedures $85.20
Infusion drug cost $214.00
Life-years lost due to events (3% discount) 0.7644
Life expectancy* (3% discount) 13.0265
Quality-adjusted life expectancy (3% discount) 12.9457
Cost beyond trial period $67,986.00
Lifetime cost $79,115.00Life expectancy was estimated on the basis of the patient’s age and estimated life-years lost due to eve
CI  confidence interval;   change; QALY  quality-adjusted life-years; UFH  unfractionated heparnd 12.0% in the UFH group (relative risk reduction 17%,
5% CI: 10% to 23%; absolute risk reduction 2.1%, p 
.001) (Table 1). The beneficial effect of enoxaparin on the
rimary end point was consistent in the pre-specified
ubgroups. The treatment benefits of enoxaparin emerged at
8 h, at which time there was a 33% reduction in relative
isk (95% CI: 13% to 48%) and a 0.5% in absolute risk
eduction of nonfatal MI, as compared with treatment with
FH (p  0.002). The incidence of major bleeding epi-
odes was increased in the enoxaparin group (2.1% vs. 1.4%,
 0.001); however, the net clinical benefit, demonstrated
y decreased rates of the composites of death, nonfatal MI,
r nonfatal intracranial hemorrhage, was observed in the
noxaparin group (relative risk reduction 17%, 95% CI: 0.10
o 0.23, p  0.001; and absolute risk reduction 2.1%).
osts and life-years lost, QALY lost for 30 days and
ifetime. Table 2 lists Framingham data on life expectancy
y age and sex (8,24). The index hospital lengths of stay
ere 11.3 8.1 days for the enoxaparin group (n 10,064)
nd 11.2  8.0 days for the UFH group (n  10,048; p 
.64). The costs of the index hospitalization trended lower
n the enoxaparin group ($9,620 vs. $9,746, difference:
$126, 95% CI: $295 to $49) (Table 3). The point
stimate of costs of subsequent hospitalization were $38
igher for the enoxaparin group ($1,210 vs. $1,171, 95%
I: $93 to $174), and the costs of the subsequent
utpatient procedure trended $11 lower for the enoxaparin
roup ($85 vs. $96, 95% CI: $28.5 to $4.2). The cost of
reatment with enoxaparin was estimated as $201 higher
han with UFH, including index and follow-up infusion
rug cost. Total 30-day costs trended $102 higher for
noxaparin ($11,129 vs. $11,016, 95% CI of the difference:
$109 to $314). Costs beyond the trial period were
1,105 higher in the enoxaparin group (95% CI: $412 to
1,798), which was calculated on the basis of the remain-
ng life expectancy of patients in treatment groups and
he average per capita of $5,219 in 2004. Total lifetime
osts (30-day costs plus the costs beyond trial period)
ere $1,207 higher in the enoxaparin group (95% CI:
491 to $1,923), consistent with the fact that patients in
Groupy Treatment Group
FH (n  10,223)  (Enoxaparin  UFH) 95% CI of 
$11,026.00 $102.50 $108.50 to $313.60
$9,745.80 $125.60 $294.60 to $49.20
$1,171.00 $38.50 $93.50 to $174.20
$96.50 $11.4 $28.50 to $4.20
$13.00 $201.00 $28.00 to $514.00
0.8803 0.1158 0.0405 to 0.1880
12.8149 0.2116 0.079 to 0.3442
12.6908 0.2549 0.1206 to 0.3892
$66,881.00 $1,105.00 $412.00 to $1,798.00
$77,907.00 $1,207.00 $491.00 to $1,923.00ente b
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September 29, 2009:1271–9 Cost Effectiveness of Enoxaparin in STEMIhe enoxaparin group had a longer life expectancy (Table
). The impact of end points on cost was reflected in the
ost beyond the trial period and lifetime cost, which were
ignificantly different between the 2 arms.
ost-effectiveness analysis for 30 days and lifetime. Table 4
hows the cost-effectiveness analysis for 30 days and lifetime.
atients in the enoxaparin arm gained an average of 0.12
ife-years relative to patients in the UFH arm. At 30 days, the
se of enoxaparin in patients with STEMI resulted in a 17%
elative risk reduction (95% CI: 0.10 to 0.23) and a 2.1%
bsolute risk reduction of death or nonfatal MI (p 0.001).
oughly 16.1% of all estimates were in the lower right
uadrant of the cost-effectiveness plane, indicating a mod-
rate probability of the enoxaparin strategy providing better
linical outcomes without additional cost (dominant), and
nly 0.06% in the upper left quadrant, indicating a low
robability that the enoxaparin strategy provides worse
linical outcomes at greater cost (dominated). At 30 days,
he ICER of enoxaparin compared with UFH was $880 per
YG, with 99.1% of observations $10,000/LYG, and
9.9% $50,000/LYG (Fig. 1). For lifetime, the ICER of
noxaparin compared with UFH was $5,700/LYG, with
9.9% of estimates falling below the $50,000/LYG threshold.
ost EffectivenessTable 4 Cost Effectiveness
 Cost  Effectiveness
30 days $102.50 0.1158 $
Lifetime $1,207.00 0.2116 $5
Lifetime QALY $1,207.00 0.2549 $4
CER  incremental cost-effectiveness ratio; LYG  life-years gained; other abbreviations as in Ta
Figure 1 Cost-Effectiveness Plane for the 30-Day Analysis
Scatterplot of the joint distribution of cost and effectiveness differences in the cosimilar results were observed when cost per QALY was used to
alculate ICER ($4,700/LYG) (Table 4) (Fig. 2). The QALYs
ere estimated on the basis of the different utilities for the
uality of life impact of stroke and MI. The utilities were taken
rom the Cost-Effectiveness Analysis Registry (25). The utility
f a patient suffering a stroke was estimated at 0.6 with a range
f 0.4 to 0.8, and the utility of MI was 0.8 with a range of 0.3
o 0.9.
The results for subgroup analysis for 30 days and lifetime,
et benefit, and multinational clinical trial data and country-
pecific cost-effectiveness analysis are shown in the Online
ppendix.
ensitivity analysis for 30 days and lifetime. The life
xpectancy gain with enoxaparin relative to UFH may be
maller or larger than projected, which would then affect the
CER. To account for this, we varied LYG with enoxaparin
ystematically by 10%, 20%, 30%, and 40%, and calculated
he ICERs associated with these estimates. Over a lifetime,
f the estimated LYG with enoxaparin relative to UFH
ecreased by 10%, 20%, 30%, and 40%, the ICERs would
ncrease from $5,700 to $6,300, $7,100, $8,200, and $9,500
er LYG, respectively (Fig. 3). In contrast, if the estimated
YG with enoxaparin relative to UFH increased by 10%,
Dominant% Dominant% <$50,000/LYG%
0 0.1 16.1 NA
0 0 0 99.90
0 0 0 99.90
and 3.
tiveness plane for the 30-day analysis. UFH  unfractionated heparin.ICER
880.0
,700.0
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Cost Effectiveness of Enoxaparin in STEMI September 29, 2009:1271–90%, 30%, and 40%, the ICERs would decrease from
5,700 to $5,200, $4,800, $4,400, and $4,100 per LYG,
espectively. For QALYs estimated based on the different
tilities for the quality of life impact of stroke and MI, the
CER would be $4,700 per QALY gained. The ICERs
ange from $3,400 to $7,900 per QALY gained by assuming
dditional 10%, 20%, 30%, and 40% increase or decrease of
YG with enoxaparin relative to UFH (Fig. 3).
The characteristics of variables used in the probabilistic
ensitivity analysis are shown in Table 5. The distributional
ssumptions of the cost data were based on the actual data
n this study, and their ranges come from relevant literature
14,15). Probabilities of effectiveness were derived from
merican Heart Association statistics and other cardiovas-
ular studies (26,27). The contour plot of simulated distri-
ution of mean differences in cost and effectiveness in
ALYs based on the probabilistic sensitivity analysis over a
ifetime is shown in Figure 4A. The plot of the joint
Figure 2 Cost-Effectiveness Plane and
Acceptability Curve for the Lifetime Analysis
Scatterplot of the joint distribution of cost and effectiveness differences in the
(A) cost-effectiveness plane and (B) acceptability curve for the lifetime analy-
sis. ICER  incremental cost-effectiveness ratio; UFH  unfractionated
heparin.osterior illustrates the positive dependent correlation be- sween mean differences in cost and effectiveness in QALYs.
he ellipses indicate 50%, 95%, and 99% CIs of the
imulated lifetime ICERs. It reveals that the lifetime
ALY gained could range from 0 to about 1 year for the
noxaparin compared with the UFH group, and the cost for
he enoxaparin group would vary from about the same to
5,000 higher, compared with the UFH group, indicating a
ore effective strategy at a higher cost.
The cost-effectiveness acceptability curve (Fig. 4B) shows
hat the variation in this sensitivity analysis was greater than
oted purely by the play of chance in the base case (Fig. 2),
nd that there was about 90% probability of the enoxaparin
eing cost effective at the $50,000 threshold. Taking into
ccount a number of different probabilities for variables in
he cost-effectiveness analysis, the posterior probability is
.96 that enoxaparin is more effective, 0.06 that it costs less,
nd approximately 0.03 that it dominates UFH.
iscussion
e performed the first cost-effectiveness analysis of the
xTRACT–TIMI 25 trial. When thrombolytic therapy is
sed in the setting of STEMI, enoxaparin is both effective
nd cost effective compared with UFH, with an ICER of
5,700/LYG and 99.8% of estimates falling below the
50,000/LYG benchmark (28,29). A strength of our anal-
sis is the fact that patient-level data were used directly from
he ExTRACT–TIMI 25 trial. In addition, the sensitivity
nalyses for 30 days and lifetime confirmed the robustness of
he results. To account for uncertainty in the input variables
n the cost-effectiveness calculations, probabilistic sensitivity
nalysis was performed, providing a more comprehensive
pproach to sensitivity analysis than traditional 1-way and
ultiway analyses, and confirming the high probability that
noxaparin is cost effective.
The use of enoxaparin, as compared with UFH, as
djunctive therapy for fibrinolysis in patients with STEMI
esults in reduction of death or nonfatal recurrent MI and
eduction in the composite of death, nonfatal reinfarction,
r urgent revascularization (1). Net clinical benefit of
noxaparin over UFH was demonstrated by reduction in the
ates of composites of death, nonfatal MI, nonfatal disabling
troke, nonfatal major bleeding, and nonfatal intracranial
emorrhage in the enoxaparin group, despite a higher
ncidence of major bleeding episodes among patients ran-
omly allocated to enoxaparin. Subsequent analyses have
hown that this strategy reduces death and recurrent MI in
atients who achieve early ST-segment resolution after
hrombolytic therapy (30). The clinical benefits of using
noxaparin instead of UFH as adjunctive therapy for fibri-
olysis in patients with STEMI appears to be independent
f the lytic choice and has been observed with fibrin-specific
ytics as well as with streptokinase (31). Concomitant
reatment with clopidogrel does not reduce these benefits
32). The net clinical benefit of this strategy has also been
hown in patients with renal dysfunction (33). In addition,
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September 29, 2009:1271–9 Cost Effectiveness of Enoxaparin in STEMIhe use of enoxaparin was associated with decreased inci-
ence of death or recurrent MI in those patients who
nderwent subsequent PCI (34) without an increased risk of
leeding complications. Women appear to have similar
elative and greater absolute risk reductions than men when
noxaparin is used with lytic therapy (35). Elderly patients
ain benefits from this strategy that are similar to those for
ounger patients (36).
tudy limitations. ExTRACT–TIMI 25 was a multina-
ional trial with few patients enrolled in the U.S. We
Figure 3 Sensitivity Analysis
Sensitivity analysis showing the effect of the additional 10% to 40% increase or de
heparin (UFH) on the incremental cost-effectiveness ratio (ICER). The black line in
gained.
Characteristics of Variables in the Analysis of PTable 5 Characteristics of Variables in the A
Base
Effectiveness
Cardiovascular disease (mortality)
AMI (prevalence)
Stroke (prevalence)
Quality-adjusted life-years lost
Utility for stroke
Utility for MI (including AMI)
Cost
In trial
Initial cost $2,4
Revascularization hospitalization $4,6
Other cardiovascular hospitalization $3,6
Medication: enoxaparin $2
Medication: UFH $
Outpatient service $2
Bleeding $2
Beyond trial period $65,0AMI  acute myocardial infarction; other abbreviations as in Tables 1 and 3.pplied U.S. costs to trial-wide hospitalizations on the basis
f DRGs. This method may not fully account for potential
ifferences in treatment practices and resource use between
ountries or health care systems. A large proportion of patients
ame from countries like the Russian Federation (2), where the
hreshold for hospitalization may be significantly different from
hat in a U.S. hospital, and physician costs may be underesti-
ated or overestimated. In addition, in the U.S., most patients
ith STEMI would undergo primary PCI, rather than fibri-
olysis. Cost-effectiveness analyses have also been conducted
e of life-years gained (LYG) for enoxaparin compared with unfractionated
ICER in LYG; the fuschia line indicates ICER in quality-adjusted life-years (QALY)
ilistic Sensitivity Analysissis of Probabilistic Sensitivity Analysis
Range Distribution
7 0.003–0.20 Beta
5 0.037–0.30 Beta
7 0.016–0.40 Beta
3 0.50–2.60 Gamma
0.40–0.80 Beta
0.30–0.90 Beta
$1,200–$6,710 Gamma
$1,840–$10,760 Gamma
$1,200–$9,620 Gamma
$100–$400 Log-normal
$10–$80 Log-normal
$50–$670 Gamma
$100–$1000 Normal
$45,000–$109,000 Normalcreas
dicatesrobabnaly
Value
0.078
0.118
0.025
0.806
0.60
0.80
00
00
00
10
15
00
00
00
b
S
b
m
c
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o
m
a
f
m
w
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pain, and the results indicate similar conclusions.
We used the Framingham study data, an external data-
ase, to estimate life expectancy. The Framingham database
ay not reflect multiple advances in medical care, specifi-
ally in cardiovascular medicine, that have occurred since
hat database was created. The life expectancy estimated in
ur analysis may not include the potential mortality benefits
f contemporary therapy. This strengthens our results by
aking them more conservative. In addition, use of enox-
parin as an adjunct to fibrinolysis for STEMI remains
Figure 4 Probabilistic Sensitivity Analysis
Contour plot of simulated distribution of mean differences in cost and effective-
ness on the basis of (A) the probabilistic sensitivity analysis over a lifetime
and (B) the cost-effectiveness acceptability curve. ICER  incremental cost-
effectiveness ratio; QALY  quality-adjusted life-years; UFH  unfractionated
heparin.avorable after application of various assumptions in esti-
1ating lost life expectancy due to death, MI, and stroke,
hich makes the results of this economic analysis robust.
onclusions
he cost-effectiveness analysis of the ExTRACT–TIMI 25
rial data shows that, using a U.S. model of health care
conomics, the strategy of using enoxaparin instead of UFH as
djunctive therapy for fibrinolysis in patients with STEMI is
ost effective according to commonly used benchmarks.
eprint requests and correspondence: Dr. William S. Wein-
raub, Christiana Care Center for Outcomes Research, Christiana
are Health System, 4755 Ogletown-Stanton Road, Newark,
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